| ISU ABXIS |
| ㆍCompany |
ISU ABXIS |
| ㆍCountry |
South Korea |
| ㆍSpecialty |
Mabs, Biosimilar |
| ㆍSales($,M) |
3 |
| ㆍHomepage |
 |
| ㆍArea |
Biotechnology |
| ㆍAreas of Interest |
N/A |
|
 Company Overview |
| ISU ABXIS is a leading biotech company in the areas of therapeutic monoclonal antibody. The firm was established in 2001 and was listed on the Stock Exchange in 2009. It is one of the 17 subsidiaries of conglomerate ISU Group. Its main business includes medical business like MABs and diagnostic business such as chemotherapy response assay. The medical business accounts for 52% of its annual sales. As of now, export is still smaller compared with its domestic sales ($2.5M) but as product approvals for its first biosimilar, Abciximab, are expected in more countries, export sales will likely give boost to the company's further growth. The products on its pipeline encompass the firm's second biosimilar, immiglucerase, for Gaucher disease and anti-inflmmatory therapeutic antibody for asthma etc. Its R&D expense is approximately $3.8M. Total employees are 90. |
Updated on May 11, 2011
|
| ㆍFirst Name |
Inkyung |
| ㆍLast Name |
Shin |
| ㆍDepartment |
Business Development |
| ㆍTitle |
Senior Manager |
| ㆍE-mail |
 |
| ㆍPhone |
N/A |
* If you’d like to add your contact information
for your company here, please go to MyPage
after login.
|
